Novel adjuvant approaches aiming to eradicate MRD are emerging following the highly successful paradigm of prolonged HER2-blockade, such as long-term metronomic adjuvant chemotherapy for triple-negative BC [30] or adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitors for HR-positive, HER2-negative BC [31]. This evidence concerns the gene ERBB2 and breast cancer.